Suppr超能文献

早期乳腺癌保乳患者全层病理处理的成本效益分析

Cost-effectiveness analysis of whole-mount pathology processing for patients with early breast cancer undergoing breast conservation.

作者信息

Hong N J Look, Clarke G M, Yaffe M J, Holloway C M B

机构信息

Division of Surgical Oncology, Sunnybrook Health Sciences Centre, Toronto, ON;; Department of Surgery, University of Toronto, Toronto, ON;

Sunnybrook Research Institute, Toronto, ON.

出版信息

Curr Oncol. 2016 Feb;23(Suppl 1):S23-31. doi: 10.3747/co.23.2917. Epub 2016 Feb 29.

Abstract

BACKGROUND

Obtaining accurate histopathologic detail for breast lumpectomy specimens is challenging because of sampling and loss of three-dimensional conformational features with conventional processing. The whole-mount (wm) technique is a novel method of serial pathologic sectioning designed to optimize cross-sectional visualization of resected specimens and determination of margin status.

METHODS

Using a Markov chain cohort simulation cost-effectiveness model, we compared conventional processing with wm technique for breast lumpectomies. Cost-effectiveness was evaluated from the perspective of the Canadian health care system and compared using incremental cost-effectiveness ratios (icers) for cost per quality-adjusted life-year (qaly) over a 10-year time horizon. Deterministic and probabilistic sensitivity analyses were performed to test the robustness of the model with willingness-to-pay (wtp) thresholds of $0-$100,000. Costs are reported in adjusted 2014 Canadian dollars, discounted at a rate of 3%.

RESULTS

Compared with conventional processing, wm processing is more costly ($19,989 vs. $18,427) but generates 0.03 more qalys over 10 years. The icer is $45,414, indicating that this additional amount is required for each additional qaly obtained. The model was robust to all variance in parameters, with the prevalence of positive margins accounting for most of the model's variability.

CONCLUSIONS

After a wtp threshold of $45,414, wm processing becomes cost-effective and ultimately generates fewer recurrences and marginally more qalys over time. Excellent baseline outcomes for the current treatment of breast cancer mean that incremental differences in survival are small. However, the overall benefit of the wm technique should be considered in the context of achieving improved accuracy and not just enhancements in clinical effectiveness.

摘要

背景

由于传统处理方法存在采样问题以及三维构象特征的丢失,获取乳腺肿块切除术标本的准确组织病理学细节具有挑战性。整装(wm)技术是一种新型的连续病理切片方法,旨在优化切除标本的横断面可视化并确定切缘状态。

方法

我们使用马尔可夫链队列模拟成本效益模型,比较了乳腺肿块切除术的传统处理方法与wm技术。从加拿大医疗保健系统的角度评估成本效益,并在10年的时间范围内使用每质量调整生命年(qaly)成本的增量成本效益比(icers)进行比较。进行确定性和概率敏感性分析,以测试模型在支付意愿(wtp)阈值为0至100,000美元时的稳健性。成本以调整后的2014年加拿大元报告,贴现率为3%。

结果

与传统处理相比,wm处理成本更高(19,989美元对18,427美元),但在10年内产生的qaly多增加0.03。icer为45,414美元,表明每获得一个额外的qaly需要额外支付该金额。该模型对所有参数变化都具有稳健性,切缘阳性的患病率占模型变异性的大部分。

结论

在支付意愿阈值为45,414美元之后,wm处理变得具有成本效益,最终随着时间的推移复发更少,qaly略多。目前乳腺癌治疗的良好基线结果意味着生存率的增量差异很小

相似文献

2
Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D.
Breast Cancer Res Treat. 2015 Feb;150(1):169-80. doi: 10.1007/s10549-015-3309-3. Epub 2015 Feb 19.
4
Cost-effectiveness of spinal cord stimulation therapy in management of chronic pain.
Pain Med. 2013 Nov;14(11):1631-49. doi: 10.1111/pme.12146. Epub 2013 May 24.
5
Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancer.
Acta Oncol. 2014 Feb;53(2):201-8. doi: 10.3109/0284186X.2013.840740. Epub 2013 Oct 14.
6
Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
Clin Ther. 2011 Oct;33(10):1446-55. doi: 10.1016/j.clinthera.2011.09.016. Epub 2011 Oct 11.
7
Cost effectiveness of mesh prophylaxis to prevent parastomal hernia in patients undergoing permanent colostomy for rectal cancer.
J Am Coll Surg. 2014 Jan;218(1):82-91. doi: 10.1016/j.jamcollsurg.2013.09.015. Epub 2013 Sep 29.
9
Cost effectiveness of intrathecal drug therapy in management of chronic nonmalignant pain.
Clin J Pain. 2013 Feb;29(2):138-45. doi: 10.1097/AJP.0b013e31824b5fc9.

引用本文的文献

本文引用的文献

1
Whole-mount pathology of breast lumpectomy specimens improves detection of tumour margins and focality.
Histopathology. 2016 Jul;69(1):35-44. doi: 10.1111/his.12912. Epub 2016 Jan 19.
2
Willingness to pay to avoid metastatic breast cancer treatment side effects: results from a conjoint analysis.
Springerplus. 2014 Jul 10;3:350. doi: 10.1186/2193-1801-3-350. eCollection 2014.
3
Tumor shrinkage associated with whole-mount histopathologic techniques in oral tongue carcinoma.
Pathol Res Pract. 2015 May;211(5):398-403. doi: 10.1016/j.prp.2015.01.009. Epub 2015 Feb 13.
4
Health system costs for stage-specific breast cancer: a population-based approach.
Curr Oncol. 2014 Dec;21(6):281-93. doi: 10.3747/co.21.2143.
8
A novel, automated technology for multiplex biomarker imaging and application to breast cancer.
Histopathology. 2014 Jan;64(2):242-55. doi: 10.1111/his.12240. Epub 2013 Nov 5.
9
3D Pathology Volumetric Technique: A Method for Calculating Breast Tumour Volume from Whole-Mount Serial Section Images.
Int J Breast Cancer. 2012;2012:691205. doi: 10.1155/2012/691205. Epub 2012 Dec 23.
10
Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer.
Oncologist. 2012;17(2):164-71. doi: 10.1634/theoncologist.2011-0379. Epub 2012 Feb 2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验